Replimune Group Inc. (REPL)
NASDAQ: REPL
· Real-Time Price · USD
8.98
-0.39 (-4.16%)
At close: May 30, 2025, 3:59 PM
8.97
-0.11%
After-hours: May 30, 2025, 05:49 PM EDT
-4.16% (1D)
| Bid | 8.57 |
| Market Cap | 692.24M |
| Revenue (ttm) | 4.04M |
| Net Income (ttm) | -228.24M |
| EPS (ttm) | -3.07 |
| PE Ratio (ttm) | -2.93 |
| Forward PE | -2.91 |
| Analyst | Buy |
| Ask | 8.98 |
| Volume | 1,759,905 |
| Avg. Volume (20D) | 1,052,404 |
| Open | 9.29 |
| Previous Close | 9.37 |
| Day's Range | 8.62 - 9.26 |
| 52-Week Range | 4.93 - 17.00 |
| Beta | 0.68 |
About REPL
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol REPL
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for REPL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts4 months ago
+9.87%
Replimune Group shares are trading higher after HC...
Unlock content with
Pro Subscription
4 months ago
+16.86%
Replimune Group shares are trading higher after the company announced the FDA has accepted the biologics license application for RP1 in combination with nivolumab for patients with advanced melanoma
1 month ago · seekingalpha.com
Replimune: Scope Goes Beyond That Of RP1 Oncolytic Targeting For MelanomaReplimune Group, Inc.'s BLA of RP1 + OPDIVO in advanced melanoma received an FDA Priority Review, with a PDUFA date set for July 22, 2025. RP2, adding an anti-CTLA-4 component, is being tested in meta...